May 10, 2007

SLIDES

Risks and Indications for RBCs Transfusions, David Stroncek, MD, Chief, Laboratory Services Section, Department of Transfusion Medicine, NIH (ppt) (htm)

Sponsor Presentation

Introduction, Roger M. Perlmutter, M.D., Ph.D. Executive Vice President Research & Development, Amgen Inc. (ppt) (htm)

Clinical Perspectives on ESAs, Jeffrey Crawford, M.D., Chief of Medical Oncology, Duke University (ppt) (htm)

Benefit/Risk of ESAs, Roy Baynes, M.D., Ph.D., Vice President, Global Development, Oncology Supportive Care, (ppt) (htm)

Alex Zukiwski, M.D., Vice President, Johnson Pharmaceutical Research and Development (ppt) (htm)

Summary, Roger M. Perlmutter, M.D., Ph.D. Executive Vice President Research & Development, Amgen Inc. (ppt) (htm)

Core and Back up Slides (ppt) (pdf)

Food and Drug Administration Presentation

Continuing Reassessment of the Risks of Erythropoiesis-Stimulating Agents (ESAs) in Patients with Cancer, Vinni Juneja, M.D., Medical Officer, Office of Oncology Drug Products (OODP), FDA (ppt) (htm)

Back up Slide (ppt) (htm)

Open Public Hearing Speakers

Clinical importance and safety of ESAs for patients with Myelodysplastic Syndromes (MDS), Steven Gore, M.D., Johns Hopkins Oncology Center, Baltimore, MD, (ppt) (htm)

Up | AC Home Page